Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KER-065 in Duchenne Muscular Dystrophy
NCT07704099Phase 2Recruiting
- Sponsor
- Keros Therapeutics
- Start
- Sep 2026
- Primary completion
- Aug 2028
- Countries
- 2
01
Overview
Phase 2, open-label trial of KER-065 in Duchenne muscular dystrophy (DMD) (3 cohorts), sponsored by Keros Therapeutics. Primary endpoint: Treatment-Emergent Adverse Events and Serious Adverse Events at 14 months. Started Sep 2026; status: recruiting.
02
Drugs
KER-065
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT07704099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07704099.